CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: To obtain a global overview of metabolism during TKI treatment, we performed steady state analysis on imatinib-treated primary CML CD34+ cells, focusing on metabolites that can be reproducibly detected in primary samples (Fig. 2f).